162 related articles for article (PubMed ID: 19104437)
1. Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer.
Turner J; Chaudhary U
Anticancer Drugs; 2009 Mar; 20(3):215-6. PubMed ID: 19104437
[TBL] [Abstract][Full Text] [Related]
2. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
3. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
5. Unexpected response of hormone-refractory prostate cancer to treatment with an antileukemic chemotherapy regimen.
Gandhok N; Sartor O
Urology; 2004 Oct; 64(4):807-9. PubMed ID: 15491730
[TBL] [Abstract][Full Text] [Related]
6. Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal.
Kundranda MN; Muslimani A; Daw HA; Spiro TP
Clin Genitourin Cancer; 2007 Sep; 5(6):401-2. PubMed ID: 17956714
[TBL] [Abstract][Full Text] [Related]
7. Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis.
Desai B; Gross ME; Jadvar H
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):231-2. PubMed ID: 22980132
[No Abstract] [Full Text] [Related]
8. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
9. [Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].
Guinot JL; Ricós JV; Gimeno J; Tortajada MI; Carrascosa M; Santos M; Casanova J; Soler P; Crispín V; Arribas L
Actas Urol Esp; 2011 Jun; 35(6):339-44. PubMed ID: 21481974
[TBL] [Abstract][Full Text] [Related]
10. Biochemical remission after resection of prostate cancer lung metastasis.
Chao DH; Higgins JP; Brooks JD
Urology; 2004 Mar; 63(3):584-5. PubMed ID: 15028469
[TBL] [Abstract][Full Text] [Related]
11. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Lloyd A; Penson D; Dewilde S; Kleinman L
Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
[TBL] [Abstract][Full Text] [Related]
12. Synchronous male breast cancer and carcinoma of prostate in 90-year-old male, presented with spinal cord compression and multiple spine lytic lesions.
Grenader T; Shavit L
Breast J; 2007; 13(4):410-2. PubMed ID: 17593047
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Sartor O
J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
[TBL] [Abstract][Full Text] [Related]
14. Lack of energy, petechiae, elevated PSA level--Dx?
Subramaniam S; Choufani E; Manov A
J Fam Pract; 2014 Oct; 63(10):565-7. PubMed ID: 25343154
[No Abstract] [Full Text] [Related]
15. Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Njiaju UO; Truica CI
Clin Breast Cancer; 2010 Feb; 10(1):E3-5. PubMed ID: 20133250
[TBL] [Abstract][Full Text] [Related]
16. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita H; Kawakami S; Fukui I
Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
[No Abstract] [Full Text] [Related]
17. [Solitary peritoneal carcinomatosis in prostate cancer].
Brehmer B; Makris A; Wellmann A; Jakse G
Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
[TBL] [Abstract][Full Text] [Related]
18. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
19. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy.
Kaufman DS; McDougal WS; Zietman AL; Harisinghani MG; Young RH
N Engl J Med; 2004 Jul; 351(2):171-8. PubMed ID: 15247358
[No Abstract] [Full Text] [Related]
20. Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature.
Pinto F; Brescia A; Sacco E; Volpe A; Gardi M; Gulino G; Bassi P
Arch Ital Urol Androl; 2009 Dec; 81(4):212-4. PubMed ID: 20608143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
